Fully financed Phase III program for Mangoral through the IPO
Ascelia Pharma AB (publ) (ticker: ACE) today announced that its interim report for the period January-March 2019 is now available on the company’s website: https://www.ascelia.com/tag/reports-presentations/IMPORTANT EVENTS IN THE PERIOD · IPO of SEK 200 million · More than 6,000 new shareholders in the IPO – both institutional and private · Fully financed Phase III program for Mangoral IMPORTANT EVENTS AFTER THE PERIOD · Encouraging results from Oncoral’s Phase I combination study with oral capecitabine · IPO overallotment utilised raising SEK 22 million ·